China Sxt Pharmaceuticals, Inc. (NASDAQ:SXTC)

TAIZHOU, China, March 16, 2020 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS") announced today that a fund granted to the Company for the key techniques incorporated into advanced Directly-Oral TCMPs derived from agriculture has been approved on February 19, 2020, by the Hailing District Science and Technology Bureau of Taizhou city.

The grant is founded by the Scientific and Technologic Development Program of Hailing District and supported by the Hailing District government. Our project is about the development of the key technologies used in medical herb planting pre-processing of raw materials for Directly-Oral TCMP products. The Company will develop a one-stop system from medical herb planting to the finished products of TCMPs, which enables the Company to track and ensure products' qualities. The Company is expected to further its lead on research and development of specialized Advanced TCMPs and receive additional benefits when marketing its new Advanced TCMP products in the future. 

Dr. Jing-Zhen Deng, Chief Scientific Officer and Chief Operating Officer of China SXT, commented, "This grant supported by the local government can contribute to our continuous effort in leading research and development of new advanced TCMPs and chase of higher quality of the products. We believe it will further strengthen our R&D capabilities in our new Advanced TCMPs, which is expected to eventually help expanding our market share in our advanced Directly-Oral TCMP products."